| Literature DB >> 31345142 |
Paolo Fogagnolo1, Giulia Torregrossa1, Laura Tranchina1, Antonio Ferreras2, Stefano De Cillá3, Antoine Labbé4, Michele Figus5, Laura Ottobelli1, Luca Rossetti1.
Abstract
Glaucoma is the second leading cause of blindness in the world, affecting more than 60 million people globally. In order to reduce the progression of the disease, both medical and surgical treatments are used. Frequent side effects of both treatments include a range of modifications of the ocular surface grouped as the Ocular Surface Disease (OSD), which include Dry Eye Disease (DED). DED and other OSD negatively impact on the success of anti-glaucoma treatments and reduce the adherence to medical therapies. Tear film osmolarity (TFO) is a relatively novel test which has become a hallmark of DED. The aim of this paper was to review the association between OSD, DED and glaucoma in view of published TFO data, and to discuss future fields of research and treatments on the topic of glaucoma iatrogenic damage. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Tear film osmolarity; benzalkonium chloride; blindness; dry eye disease; glaucoma; ocular surface disease.
Mesh:
Substances:
Year: 2019 PMID: 31345142 DOI: 10.2174/0929867326666190725160621
Source DB: PubMed Journal: Curr Med Chem ISSN: 0929-8673 Impact factor: 4.530